Skip to main content

Month: June 2025

NXP and Rimac Technology Co-Develop Centralized Vehicle Architecture for Advanced Domain and Zonal Control

NXP and Rimac Technology Co-Develop Centralized Vehicle Architecture for Advanced Domain and Zonal ControlNXP and Rimac Technology’s jointly developed architecture provides an easy-to-use platform that allows the development and efficient integration of many different vehicle applications such as vehicle dynamics and charging control, energy and thermal management, and body electronics. The S32E2, at the heart of it, allows the consolidation of over 20 ECUs into just three centralized units.Rimac Technology is the first to deploy NXP’s S32E2 real-time processor series in its upcoming next-generation ECU platform for software-defined vehicles (SDV) NXP and Rimac’s jointly developed centralized architecture consolidates more than 20 electronic control units into just three centralized units Collaboration enables OEMs to adopt SDV...

Continue reading

Aerospace and defense leaders are prioritizing digital continuity to tackle industry disruption

Press contact: Florence Lièvre Tel.: +33 1 47 54 50 71Email: florence.lievre@capgemini.com Aerospace and defense leaders are prioritizing digital continuity to tackle industry disruption77% of aerospace and defense leaders believe improving digital continuity will accelerate production ramp-up as it drives shorter time to market, with a 13% reduction on average More than 8 out of 10 (86%) defense organizations recognize the need to integrate AI and gen AI in engineering and product development Paris, June 12 2025 – The Capgemini Research Institute’s latest report, ‘The strategic edge: How digital continuity drives business outcomes in aerospace and defense,’ published today, finds that digital continuity1 – the seamless integration of data and information across all stages of the product lifecycle and linked to the external partner...

Continue reading

Orange: Orange intends to issue a new series of Euro-denominated hybrid notes and to launch a tender offer on some of its outstanding hybrid notes

Press releaseParis, 12 June 2025 NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA Orange intends to issue a new series of Euro-denominated hybrid notes and to launch a tender offer on some of its outstanding hybrid notes Orange S.A. (the Company) is today announcing its intention to issue Euro denominated undated deeply subordinated fixed to reset rate notes with a first call date as of 24 June 2032 (the New Notes). The pricing of the New Notes is expected to be announced later today. The New Notes are intended to be admitted to trading on Euronext Paris. It is also expected that the rating agencies will assign the New Notes a rating of BBB-/Baa3/BBB- (S&P / Moody’s / Fitch) and an equity content of 50%. The Company is also launching a tender offer (the Tender Offer) to repurchase:its €1.25 billion Undated 12 Year Non-Call...

Continue reading

Clariane completes its plan to strengthen its financial structure with the disposal of its Petits-fils home care services network

Press release June 12th, 2025         Clariane completes its plan to strengthen its financial structure with the disposal of its Petits-fils home care services networkParis, June 12th, 2025 – Clariane (CLARI.PA – ISIN FR0010386334), announces today the signing of an agreement for the disposal of its Petits-fils network to Crédit Agricole Santé & Territoires for a gross disposal value of €345 million. Subject to the fulfillment of customary conditions precedent, the closing of this transaction is expected to take place in the third quarter of 2025. The disposal of the Petits-fils network, the terms of which were set following a competitive process, completes, six months ahead of schedule, the implementation of the plan announced by Clariane on 14 November 2023 to strengthen its financial structure. This plan...

Continue reading

Results for the year ended 31 March 2025

PayPoint PlcResults for the year ended 31 March 2025 Further progress towards £100m EBITDA by end of FY26 New targets established for the Group for the next three years, including share buyback programme increased and extended to at least £30 million per annum till the end of FY28 GROUP FINANCIAL HIGHLIGHTSUnderlying EBITDA1 of £90.0 million (FY24: £81.3 million) increased by £8.7 million (10.7%) Underlying profit before tax2 of £68.0 million (FY24: £61.7 million) increased by £6.3 million (10.2%) Net corporate debt7 of £97.4 million increased by £29.9 million from opening position of £67.5 million, reflecting previously announced investments and the ongoing share buyback programme Final dividend of 19.6 pence per share declared vs the final dividend for the year ended 31 March 2024 of 19.2 pence per share       Year ended 31...

Continue reading

CREDIT AGRICOLE SA: Crédit Agricole Santé & Territoires announces the signing of an agreement to acquire Petits-fils, the leading provider of at-home services for seniors in France, from Clariane

Press Release Montrouge, 12 June 2025 Crédit Agricole Santé & Territoires announces the signing of an agreement to acquire Petits-fils, the leading provider of at-home services for seniors in France, from Clariane The acquisition of Petits-fils would establish Crédit Agricole Santé & Territoires, a subsidiary of the Crédit Agricole Group, as the leader in at-home services for seniors in France. Beyond its commitment to improving access to healthcare, Crédit Agricole Santé & Territoires has invested in supporting wellbeing in aging, particularly in two key areas: non-medical accommodation — a sector in which the Group has been active since 2024 — and at-home services, where the acquisition of Petits-fils would represent a pivotal milestone in its development. The transaction is also expected to unlock synergies with other...

Continue reading

AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036

PRESS RELEASE AB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT PROTECTING THE COMPOSITION OF MATTER OF AB8939, INCLUDING ITS USE IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML), WITH PROTECTION UNTIL 2036 THIS PATENT COMPLETES INTELLECTUAL PROPERTY COVERAGE FOR AB8939 ACROSS ALL KEY GEOGRAPHIC AREAS WHERE IT COULD BE MARKETED, INCLUDING EUROPE, USA, CHINA, JAPAN AND SOUTH KOREA, INDIA, ISRAEL, LATIN AMERICA, AND AUSTRALIA Paris, 12 June, 2025, 8am CET AB Science SA (Euronext – FR0010557264 – AB) today announced that the patent office of Canada has granted a patent (CA 2975644) protecting the composition of matter of AB8939, and closely related compounds, until 2036. This patent also covers the use of AB8939 in the treatment of hematological disorders and/or proliferative disorders and provides a strong overall protection...

Continue reading

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activity DZP showed consistent improvements in fatigue, a common and debilitating symptom of systemic lupus erythematosus (SLE) At Week 48, more individuals receiving DZP experienced no or low disease activity compared to standard of care with differences observed as early as Week 12BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) — UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe...

Continue reading

SIKA IS UNLOCKING SMART AND DURABLE SOLUTIONS FOR DATA CENTER CONSTRUCTION

SIKA IS UNLOCKING SMART AND DURABLE SOLUTIONS FOR DATA CENTER CONSTRUCTION Today in Dallas, United States, Sika outlines strategic initiatives and high-performance solutions that will drive the future of data center construction. With over 1,000 data centers built using Sika solutions and a strong pipeline of new projects, Sika has become the trusted partner of technology leaders shaping digital infrastructure worldwide. Global investments in data centers are projected to exceed CHF 400 billion by 20281, driven by the surging demand for cloud computing, artificial intelligence, and the Internet of Things (IoT). With the launch of the Stargate project alone, CHF 410 billion will be invested additionally in the United States over the next four years to develop data centers and infrastructure for training and operating advanced AI systems....

Continue reading

Bigbank AS Results for May 2025

May was a stable month for Bigbank – both the loan and deposit portfolios grew at a steady pace, and profitability remained at a solid level. The loan portfolio increased by a total of 43 million euros in May. The largest contributions came from business loans and home loans, which grew by 22 million and 15 million euros, respectively. The consumer loan portfolio grew by 6 million euros. The deposit portfolio grew by a total of 26 million euros in May. In a declining interest rate environment, the savings deposit product became more attractive to customers, with its portfolio increasing by 18 million euros during the month. The term deposit portfolio also returned to growth, increasing by 8 million euros. It is encouraging that despite falling interest rates, Bigbank has increased its net interest income during the first five months of...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.